CO2021016433A2 - Derivados heterocíclicos condensados - Google Patents

Derivados heterocíclicos condensados

Info

Publication number
CO2021016433A2
CO2021016433A2 CONC2021/0016433A CO2021016433A CO2021016433A2 CO 2021016433 A2 CO2021016433 A2 CO 2021016433A2 CO 2021016433 A CO2021016433 A CO 2021016433A CO 2021016433 A2 CO2021016433 A2 CO 2021016433A2
Authority
CO
Colombia
Prior art keywords
condensed heterocyclic
heterocyclic derivatives
compounds
preparing
treatment
Prior art date
Application number
CONC2021/0016433A
Other languages
English (en)
Inventor
Zhangling Cheng
Gang Deng
Lindsey Graham Deratt
Sandrine Céline Grosse
Lili Hu
Yimin Jiang
Tim Hugo Maria Jonckers
Bart Rudolf Romanie Kesteleyn
Scott D Kuduk
Morgan Charles R Lecomte
Lamenca Carolina Martinez
Serge Maria Aloysius Pieters
Pierre Jean-Marie Bernard Raboisson
Koen Vandyck
Wim Gaston Verschueren
Yanping Xu
Jan Martin Berke
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of CO2021016433A2 publication Critical patent/CO2021016433A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La solicitud describe compuestos de derivado heterociclo condensado, composiciones farmacéuticas que comprenden estos compuestos, procedimientos químicos para preparar estos compuestos y su uso en el tratamiento de enfermedades asociadas con infección por VHB.
CONC2021/0016433A 2019-05-28 2021-12-01 Derivados heterocíclicos condensados CO2021016433A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962853533P 2019-05-28 2019-05-28
EP19176933 2019-05-28
CN2020085720 2020-04-20
PCT/US2020/034643 WO2020243135A1 (en) 2019-05-28 2020-05-27 Fused heterocyclic derivatives

Publications (1)

Publication Number Publication Date
CO2021016433A2 true CO2021016433A2 (es) 2021-12-10

Family

ID=71741889

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0016433A CO2021016433A2 (es) 2019-05-28 2021-12-01 Derivados heterocíclicos condensados

Country Status (17)

Country Link
EP (1) EP3976617A1 (es)
JP (1) JP2022535734A (es)
KR (1) KR20220012913A (es)
CN (1) CN113906028A (es)
AU (1) AU2020285718A1 (es)
BR (1) BR112021022889A8 (es)
CA (1) CA3138168A1 (es)
CL (1) CL2021003155A1 (es)
CO (1) CO2021016433A2 (es)
CR (1) CR20210666A (es)
IL (1) IL288322A (es)
JO (1) JOP20210313A1 (es)
MA (1) MA56043A (es)
MX (1) MX2021014575A (es)
PE (1) PE20220767A1 (es)
SG (1) SG11202113167QA (es)
WO (1) WO2020243135A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022116999A1 (en) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives and their use in the treatment of hbv infection
WO2022116998A1 (en) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives as hbv inhibitors
TW202237617A (zh) * 2020-12-02 2022-10-01 愛爾蘭商健生科學愛爾蘭無限公司 稠合雜環衍生物
CN117715909A (zh) 2021-06-02 2024-03-15 杨森科学爱尔兰无限公司 稠合杂环衍生物
US20240279227A1 (en) * 2021-06-02 2024-08-22 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives
WO2024114709A1 (en) * 2022-12-01 2024-06-06 Janssen Sciences Ireland Unlimited Company A crystal form of a fused heterocycle derivative compound
WO2024140851A1 (zh) * 2022-12-28 2024-07-04 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2993174A1 (en) * 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridine derivatives and their use in therapy
WO2016109684A2 (en) * 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
US10975077B2 (en) * 2016-06-29 2021-04-13 Novira Therapeutics, Inc. Diazepinone derivatives and their use in the treatment of hepatitis B infections
US10987359B2 (en) * 2016-06-29 2021-04-27 Novira Therapeutics, Inc. Oxadiazepinone derivatives and methods of treating hepatitis B infections

Also Published As

Publication number Publication date
BR112021022889A2 (pt) 2022-01-04
WO2020243135A1 (en) 2020-12-03
PE20220767A1 (es) 2022-05-16
AU2020285718A1 (en) 2022-02-03
CL2021003155A1 (es) 2022-07-22
KR20220012913A (ko) 2022-02-04
CR20210666A (es) 2022-03-11
MX2021014575A (es) 2022-05-24
BR112021022889A8 (pt) 2024-03-05
IL288322A (en) 2022-01-01
CA3138168A1 (en) 2020-12-03
CN113906028A (zh) 2022-01-07
JP2022535734A (ja) 2022-08-10
SG11202113167QA (en) 2021-12-30
EP3976617A1 (en) 2022-04-06
MA56043A (fr) 2022-04-06
JOP20210313A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
CO2021016433A2 (es) Derivados heterocíclicos condensados
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
DOP2019000117A (es) Nuevos derivados de quinolina
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112018072168A2 (pt) compostos derivados da pirimidina como inibidores da quinase jak
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
UY37741A (es) Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue
CO2019014484A2 (es) Nuevos derivados de azaquinolina
CL2017002482A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CU20170109A7 (es) Derivado de quinoleina para tratar y prevenir infecciones virales
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
CL2020002891A1 (es) Nuevos derivados de quinolina
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
UY39793A (es) Derivados heterocíclicos condensados
UY39550A (es) Derivados heterocíclicos condensados
CL2012001579A1 (es) Compuestos derivados de (heterociclo-piperidina condensada)-(piperazinil) 1-alcanona o de (heterociclo-pirrolidina condensada)-(piperazinil)-1 alcanona, inhibidores de p75; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades neurodegenerativas, esquizofrenia, entre otras; compuesto intermediario.
ECSP21092791A (es) Derivados heterocíclicos condensados
CL2011002625A1 (es) Compuestos derivados de 3-(piridin-3-il-etinil)-piridina; preparaciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes.